Medica Scientia Innovation Research S.L.

25 trials 6 recruiting Commercial sponsor

Filter these 25 trials by condition, phase, country and more.

Open in Search →

25 Registered trials

6 Recruiting

15 Completed trials

12 Countries active

56 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase III: 1 Phase II: 21 Phase I/II: 3

Oversight events:

1 serious breach 2 temporary halts across 3 trials

View oversight register →

100%

15 of 15 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

HER2 positive breast cancer 3 Breast cancer 1 Soft tissue sarcoma 1 Hormone receptor positive HER2 negative breast cancer 1 Hormone receptor positive breast cancer 1 Triple negative breast cancer 1

Top IMPs

LETROZOLE 3 TRASTUZUMAB DERUXTECAN 3 ABEMACICLIB 2 CARBOPLATIN 2 DIPHENHYDRAMINE HYDROCHLORIDE 2 EXEMESTANE 2 FULVESTRANT 2 GIREDESTRANT 2 LOPERAMIDE HYDROCHLORIDE 2 PARACETAMOL 2 PEMBROLIZUMAB 2 SACITUZUMAB GOVITECAN 2

All trials — page 2

25 total

A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LIN… Ended

2025-521489-80-00 Phase II 1 country DOMVANALIMAB; SACITUZUMAB GOVITECAN; ZIMBERELIMAB

Showing 25–25 of 25 trials

← All sponsors A–Z